Frequently asked questions
How does Jagsonpal score on the five pillars?
Jagsonpal passes three of five pillars: sunrise, iron fortress and free cash flow, with leadership and moat grading partial. Women's health and the semi-chronic shift sit inside a market growing 9 to 12%, the balance sheet holds about Rs 191 crore of cash with no effective debt, and free cash flow reached Rs 61.4 crore in FY26 at over 100% of operating PAT. The partials reflect a four-year PE-era leadership record with three integrations running at once, and a moat of prescriber habit rather than patents, already tested by counterfeiting in FY25.
Why does free cash flow pass for Jagsonpal?
DalalBytes grades Jagsonpal's free cash flow a pass because conversion is elite: free cash flow rose from Rs 7.7 crore in FY22 to Rs 61.4 crore in FY26, about eightfold, on near-zero capex and a cash conversion cycle of about 26 days, reaching about 137% of operating PAT. The scale note is that Rs 61 crore is a 4.3% yield on the market cap, and part of future cash flow is committed to the deferred wellness consideration and the Aequitas build-out.
Pillar 1: Is the sector a sunrise? (PASS)
India's pharmaceutical market grew 8.6% in FY26 and 11.6% in Q1 FY27 on Pharmarack data, and women's health sits on the faster side of it: rising IVF volumes, later pregnancies and a shift from acute to semi-chronic therapies that repeat monthly. Jagsonpal's secondary growth ran at 12.2% in FY26 and 18.9% in Q1 FY27, ahead of the market both times, with rank improving to 88. A durable, above-average demand slope in the chosen therapies, not a technology sunrise. PASS.
Pillar 2: Can the leadership execute? (PARTIAL)
Since 2022 the Convergent Finance team and the Kochhar family have divisionalised the business, lifted disclosure to presentations and concalls with checkable operating numbers, compounded operating PAT at about 24%, structured three deals with deferred or retained seller stakes, and run a Rs 40 crore buyback at a 40% premium without promoters tendering. Promoter holding is 68.82% with zero pledging. The partial is about proof: the record is four years old, three integrations run simultaneously, the Aequitas target (Rs 10 crore of EBITDA by Year 2) is aggressive, and a PE promoter eventually exits. PARTIAL, with a clear upgrade path.
Pillar 3: Does a moat protect returns? (PARTIAL)
More than 20 brands rank top five in their molecule categories, the company claims seventh in gynaecology and second in orthopaedics, about 1,000 representatives cover roughly 90% of India's gynaecologists, and gross margin of about 65% is what that franchise earns. But there is no patent behind dydrogesterone, indomethacin or hydroxyprogesterone, counterfeiters manufactured the two biggest brands in FY25 and took volume, and the top 10 brands are about 58% of revenue. A habit moat, deep and narrow, that must be policed and re-earned. PARTIAL.
Pillar 4: Is the balance sheet a fortress? (PASS)
About Rs 190.7 crore of cash at March 2026 against effectively no borrowings, net worth of Rs 276.2 crore and a 26-day cash conversion cycle. In one year the company funded a Rs 26.2 crore dividend, a Rs 40 crore buyback, Aequitas at Rs 20.8 crore and the Rs 23.7 crore wellness upfront payment, and still held about Rs 170 crore of cash after Q1 FY27. A fortress that funds its own growth programme without dilution or debt. PASS.
Pillar 5: Does the free cash flow show up? (PASS)
It shows up and compounds: Rs 7.7 crore in FY22 to Rs 61.4 crore in FY26, because growth needs representatives and short-cycle working capital, not plants, and capex rounds to zero in most years. FY26 free cash flow was about 137% of operating PAT. The only note is scale: Rs 61 crore is a 4.3% yield on a Rs 1,436 crore market cap, and part of future flow is spoken for by deferred deal consideration. On conversion quality, which is what the pillar grades: PASS.
What would change the grade?
Leadership upgrades to pass if Aequitas reaches its Year 2 EBITDA target and the wellness integration lands without margin dilution, and downgrades if a deal is written down or the promoter sells at a discount. Moat upgrades if dermatology and paediatrics reach top-tier prescriber coverage with margins intact, and downgrades if any power brand loses its top-five rank or counterfeiting recurs at scale.
© 2026 DalalBytes Research · For educational purposes only. Not investment advice.